NCT07320950 2026-01-06
Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients
Sun Yat-sen University
Phase 3 Completed
Clinical Trials
9 trialsNCT01099449 2022-11-03
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02486198 2018-02-05
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Completed
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00316914 2016-08-11
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00305188 2016-05-04
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Sanofi
Phase 3 Completed
NCT02024412 2015-09-28
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02024438 2015-09-28
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT00272051 2006-09-13
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Sanofi
Phase 3 Completed